Reports in the US press suggested Pfizer is considering either expanding its existing facility in Sanford, North Carolina or building the plant at a site nearby.
Kim Bencker, head of communications at Pfizer Global supply, told us in an emailed statement “We recently announced that we’re moving forward with scoping potential sites in Sanford for our new gene therapy site.
She added: “This work is still in the preliminary stages and we aren’t able to share additional detail at this time.”
The move follows a little over a year after the US drug manufacturer acquired Bamboo, a North Carolina-based gene therapy developer.
The deal included a recombinant Adeno-Associated Virus (rAAV) vector design and production technology, a Phase I candidate for Giant Axonal Neuropathy and a preclinical programme targeting Duchenne Muscular Dystrophy (DMD).
Pfizer also gained a 11,000sq ft gene therapy manufacturing facility in Chapel Hill that Bamboo bought from the University of North Carolina in 2016.